Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelo dysplastic syndromes)
Reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia .
Mobilisation of peripheral blood progenitor cells (PBPC) .
In patients with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5x109/L, and a history of severe or recurrent infections, long term administration of FICOCYTE is indicated to increase neutrophil counts and to reduce the incidence and duration of infection related events .
Treatment of persistent neutropenia (ANC≤1.0 x109/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other therapeutic options are inappropriate.
The safety and efficacy of FICOCYTE are similar in adults and children receiving cytotoxic chemotherapy.
